Citigroup stock dips as 1,000 job cuts loom and earnings near

Citigroup stock dips as 1,000 job cuts loom and earnings near

New York, January 13, 2026, 12:13 EST — Regular session

  • Shares of Citigroup dipped roughly 0.4% by midday trading
  • Reuters reported the bank plans to slash roughly 1,000 positions this week
  • Citi will release its quarterly earnings on Wednesday

Shares of Citigroup dipped 0.4% to $117.27 by 12:13 p.m. EST Tuesday, following a Reuters report that the bank plans to cut roughly 1,000 jobs this week. The cuts come as Citigroup moves to trim costs ahead of its quarterly earnings. A spokesperson said, “These changes reflect adjustments we’re making to ensure our staffing levels, locations and expertise align with current business needs.” (Reuters)

The cuts come at a delicate time for the stock. Investors have been pushing major U.S. banks to tighten their expense management and deliver more consistent returns as the sector approaches a new round of earnings reports.

Bank results are shaping investors’ expectations for 2026, focusing on trading gains, fee growth, and how well loan losses are controlled. JPMorgan, kicking off the reporting season for major banks this week, posted fourth-quarter profits that beat forecasts, driven by a 17% jump in markets revenue despite volatile trading conditions. (Reuters)

Policy risk is hitting card-heavy financial stocks hard, Citi included. Shares dropped 3.7% after Reuters reported Monday that President Donald Trump proposed a one-year 10% cap on credit card interest rates starting Jan. 20—a move that shook bank and consumer finance sectors. Analysts at UBS Global pointed out, “It would take an Act of Congress for such rate caps to be in place.” (Reuters)

Banks and outside experts are sparring over what could happen if Washington pushes rates down. Morningstar analyst Michael Miller called Trump’s remarks “mostly a call to action” but said there was no clear policy plan behind it. Brian Shearer, director of the Vanderbilt Policy Accelerator, shot back, saying, “The profit margins are absolutely massive” and insisted, “There really is some fat to cut.” (Reuters)

JPMorgan executives didn’t mince words on the risks. “It would be very bad for consumers, very bad for the economy,” said JPMorgan CFO Jeremy Barnum, as the KBW Bank Index slipped 0.9% in morning trading. (Reuters)

Citi’s upcoming report is the next major event to watch. The bank will drop its fourth-quarter 2025 results around 8 a.m. ET on Wednesday, followed by a webcast and conference call at 11 a.m. ET. (Citi)

Citigroup submitted a Form 8-K on Jan. 12 containing multiple supplemental indentures related to debt securities, along with other exhibits. (SEC)

Cost cuts can be a double-edged sword. Investors will watch closely for signs the savings hold up without undercutting revenue-driving teams. They’ll also be on the lookout for any hints that credit quality is slipping as politics and interest rates squeeze consumer borrowing.

Traders are zeroing in on Citi’s earnings and remarks due Wednesday. The focus will also be on whether the credit-card cap proposal gains momentum with the Jan. 20 start date looming.

Stock Market Today

  • ABBV inks drug pricing deal with Trump, joins PD-1xVEGF bandwagon
    January 13, 2026, 2:32 PM EST. AbbVie said it signed a U.S. pricing agreement with the Trump administration to cut list prices to match those in comparable developed markets, backing the MFN proposal. The deal includes a three-year exemption from import tariffs on pharmaceutical ingredients if AbbVie expands U.S. manufacturing, and a pledge to invest $100 billion over the next decade in domestic R&D and capital. The government says 16 of 17 large drugmakers have reached similar accords; Regeneron remains in talks. In a separate release, AbbVie agreed to an exclusive license with RemeGen for its PD-1xVEGF bispecific, RC148. AbbVie will pay an upfront $650 million and up to $4.95 billion in milestones, plus royalties, for rights outside Greater China. RC148 is in phase II in China, with potential in NSCLC and CRC. Competitors include Summit, BioNTech/Bristol Myers, Merck and Pfizer pursuing PD-1/VEGF programs.
Home Depot stock slips after U.S. CPI report; mortgage rates and Feb. 24 earnings in focus
Previous Story

Home Depot stock slips after U.S. CPI report; mortgage rates and Feb. 24 earnings in focus

Scorpio Tankers stock jumps nearly 9% on net-cash update as investors eye a February catalyst
Next Story

Scorpio Tankers stock jumps nearly 9% on net-cash update as investors eye a February catalyst

Go toTop